Medtronic Couples Bedside Ultrasound Push With Robotics Bet as MiniMed Split Nears Finish Line

Medtronic folds Sonus Microsystems' AI ultrasound into acute care and launches an exchange offer to spin off at least 80.1% of its MiniMed diabetes unit.

Medtronic is pressing ahead on two fronts at once: widening its acute-care monitoring toolkit through a fresh artificial-intelligence partnership, and clearing the final hurdles in the separation of its diabetes unit. The twin moves land as the medtech giant leans on a strengthened financial base to fund a sharper focus on higher-margin franchises.

Under an agreement struck on September 16, Medtronic will fold Sonus Microsystems' AI-driven ultrasound platform, the Sonus Patch, into its Acute Care & Monitoring division. Bringing wearable ultrasound into the fold is meant to give clinicians more latitude to run exams right at the patient's bedside, deepening the company's presence in intensive care and tightening the link between digital diagnostics and continuous monitoring.

MiniMed Exchange Offer Takes Shape

Running alongside that technical expansion is the long-anticipated divorce from the former diabetes business. Medtronic launched an exchange offer for the MiniMed Group on September 14, targeting the spin-off of at least 80.1 percent of the subsidiary. Shareholders who tender their Medtronic stock receive a 7 percent discount on the swap.

The transaction is designed to remain generally free of U.S. federal income tax for Medtronic and participating investors, with MiniMed set to trade as a standalone company under the ticker Nasdaq: MMED. On September 17, the company filed clarifications to the offer prospectus with the U.S. Securities and Exchange Commission, spelling out the submission deadline for guaranteed deliveries; MiniMed had previously filed its Form S-4 registration statement. Press reports put the offer at as many as 225,361,295 newly issued MiniMed common shares, and should demand outstrip supply, Medtronic can take up additional stock capped at 2 percent of outstanding shares. The offer expires on October 9, 2026.

By offloading a people-intensive segment, management aims to channel resources toward its most profitable core fields while handing existing investors a direct stake in MiniMed's future.

Robotics and Guidance Provide the Backdrop

The restructuring rests on an improving set of financials. Roughly three weeks ago, Medtronic raised the lower end of its adjusted earnings guidance for fiscal 2027 to $5.94 per share. In the first quarter of that fiscal year, revenue reached $9.756 billion, and leadership simultaneously lifted its targets for annual organic revenue growth.

That momentum coincides with a strategic push into robotic surgery. Medtronic signed a partnership worth $700 million with Cornerstone Robotics, securing distribution rights for the Sentire surgical system in selected regions outside the United States. More than a month ago, the FDA also cleared the LigaSure instrument for use on the company's own Hugo robotic platform. Together, the initiatives signal a dual-track approach — homegrown systems plus outside alliances — to move new technologies into clinical use quickly.

Analysts Weigh In as Shares Drift

In Friday's session, the stock closed at EUR 77.44, a modest daily decline of 0.4 percent, leaving a market capitalization of EUR 99.39 billion. Market watchers are focused on how the realignment will feed through to future profitability.

Analysts have been tracking the developments closely. BTIG raised its price target to $100 on September 2 with a Buy rating, while Deutsche Bank kept its Hold stance on September 3 and a $92 target. Both houses weighed in as the company's latest strategic moves took shape.

With the exchange offer's deadline approaching, attention now turns to the take-up rate among existing shareholders. How efficiently the remaining businesses generate profitable growth once diabetes is fully off the books will be the real test.